<DOC>
	<DOC>NCT02270853</DOC>
	<brief_summary>In this study it will be analyzed how often the sleep apnea syndrome can be observed in patients with newly diagnosed lung cancer with the help of ApneaLink device by ResMed.</brief_summary>
	<brief_title>SAS in Patients With Bronchial Carcinoma</brief_title>
	<detailed_description>Determination of the SAS- frequence in patients with bronchial carcinoma. The patients will be screened at home for 1 night with the ApneaLink device by ResMed. The apneaLink device is a standard screening tool for sleep apnea in clinical practice.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Carcinoma, Bronchogenic</mesh_term>
	<criteria>Patients with reasonable suspicion of bronchial carcinoma or histologically proven bronchial carcinoma, which has not been medicated until the study entry and Patients with sleep apnea who had recently been diagnosed with bronchial carcinoma. Pregnancy other already known malignancies or tumors Patients with noninvasive artificial respiration due to a chronic respiratory insufficiencies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>ApneaLink</keyword>
	<keyword>bronchial carcinoma</keyword>
	<keyword>sleep apnea screening</keyword>
</DOC>